Drug intelligence / Profile preview

ferric derisomaltose + human erythropoietin

Development stage: Unknown
Lead developer: Pharmacosmos Therapeutics
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination therapy consisting of ferric derisomaltose, an iron replacement product, and human erythropoietin, an erythropoiesis-stimulating agent. This combination is used to treat iron deficiency anemia, particularly in patients with functional iron-deficiency anemia related to cancer treatments or chronic kidney disease. The combination shows superior efficacy in improving hemoglobin levels, transferrin saturation, and ferritin levels compared to erythropoietin monotherapy.

Other names: ferric derisomaltose + darbepoetin alfa

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on ferric derisomaltose + human erythropoietin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ferric derisomaltose + human erythropoietin.

Explore the full profile